IDEAYA Biosciences (IDYA) Receives a Buy from Wedbush

Wedbush analyst Robert Driscoll reiterated a Buy rating on IDEAYA Biosciences (IDYA – Research Report) today and set a price target of $52.00. The company’s shares closed yesterday at $42.75.

According to TipRanks, Driscoll is a 4-star analyst with an average return of 9.8% and a 44.91% success rate. Driscoll covers the Healthcare sector, focusing on stocks such as Alpine Immune Sciences, Arvinas Holding Company, and Cullinan Management.

Currently, the analyst consensus on IDEAYA Biosciences is a Strong Buy with an average price target of $53.56, implying a 25.29% upside from current levels. In a report released yesterday, Capital One Financial also maintained a Buy rating on the stock with a $50.00 price target.

Based on IDEAYA Biosciences’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $3.92 million and a GAAP net loss of $33.96 million. In comparison, last year the company earned a revenue of $4.02 million and had a GAAP net loss of $24.2 million

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

IDEAYA Biosciences (IDYA) Company Description:

IDEAYA Biosciences, Inc. develops cancer therapeutics. It is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company operates and manages its business as one operating and reportable segment, which is the business of research and development for oncology-focused precision medicine. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.